Literature DB >> 17643535

Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty.

Alberto Dominguez-Rodriguez1, Sima Samimi-Fard, Martin J Garcia-Gonzalez, Pedro Abreu-Gonzalez.   

Abstract

BACKGROUND: Levosimendan is a new calcium sensitizer with positive inotropic properties. In previous studies, it has recently been shown that levosimendan improves the Doppler echocardiographic parameters of the left ventricular (LV) diastolic function in patients with anterior acute myocardial infarction. We sought to evaluate the effects of levosimendan compared to dobutamine on LV diastolic function, using conventional transmitral Doppler, in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) who subsequently developed cardiogenic shock.
METHODS: We randomized 22 consecutive STEMI patients with cardiogenic shock after primary PCI to levosimendan or dobutamine infusion and we also analyzed the diastolic function using conventional transmitral Doppler flow.
RESULTS: Twenty-four hours after the initiation of the drug infusion, patients treated with levosimendan (n=11) showed a significant reduction of the isovolumetric relaxation time (116+/-15.2-70.4+/-10.8 ms; P<.001), and a significant increase of the E/A ratio (0.6+/-0.3-1.4+/-0.5; P<.001). In the dobutamine group (n=11), no statistically significant differences were noted in the echocardiographic Doppler indexes.
CONCLUSION: Levosimendan seems to be effective in improving the Doppler echocardiographic parameters of LV diastolic function in patients with STEMI revascularised by primary PCI who developed cardiogenic shock.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17643535     DOI: 10.1016/j.ijcard.2007.05.018

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  9 in total

Review 1.  Vasopressors for acute myocardial infarction complicated by cardiogenic shock.

Authors:  R Prondzinsky; K Hirsch; L Wachsmuth; M Buerke; S Unverzagt
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-12-04       Impact factor: 0.840

2.  The Use of Levosimendan after Out-of-Hospital Cardiac Arrest and Its Association with Outcome-An Observational Study.

Authors:  Susanne Rysz; Malin Jonsson Fagerlund; Johan Lundberg; Mattias Ringh; Jacob Hollenberg; Marcus Lindgren; Martin Jonsson; Therese Djärv; Per Nordberg
Journal:  J Clin Med       Date:  2022-05-06       Impact factor: 4.964

Review 3.  Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.

Authors:  Julia Schumann; Eva C Henrich; Hellen Strobl; Roland Prondzinsky; Sophie Weiche; Holger Thiele; Karl Werdan; Stefan Frantz; Susanne Unverzagt
Journal:  Cochrane Database Syst Rev       Date:  2018-01-29

Review 4.  Use of levosimendan in patients with ischemic heart disease following mechanical reperfusion.

Authors:  Ibrahim Halil Kurt
Journal:  Surg Today       Date:  2009-04-30       Impact factor: 2.549

5.  A case study of likely wild-type cardiac transthyretin amyloidosis causing rapid deterioration.

Authors:  Thomas Davies; Aarash Saleh; Gerry Coghlan; Carol Whelan; Banwari Agarwal
Journal:  J Intensive Care Soc       Date:  2016-11-29

6.  Vasoactive pharmacologic therapy in cardiogenic shock: a critical review.

Authors:  Rasha Kaddoura; Amr Elmoheen; Ehab Badawy; Mahmoud F Eltawagny; Mohamed A Seif; Khalid Bashir; Amar M Salam
Journal:  J Drug Assess       Date:  2021-07-20

Review 7.  Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap.

Authors:  Nicolina Conti; Milo Gatti; Emanuel Raschi; Igor Diemberger; Luciano Potena
Journal:  Drug Des Devel Ther       Date:  2021-08-04       Impact factor: 4.162

Review 8.  Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.

Authors:  Zoltán Papp; Piergiuseppe Agostoni; Julian Alvarez; Dominique Bettex; Stefan Bouchez; Dulce Brito; Vladimir Černý; Josep Comin-Colet; Marisa G Crespo-Leiro; Juan F Delgado; István Édes; Alexander A Eremenko; Dimitrios Farmakis; Francesco Fedele; Cândida Fonseca; Sonja Fruhwald; Massimo Girardis; Fabio Guarracino; Veli-Pekka Harjola; Matthias Heringlake; Antoine Herpain; Leo M A Heunks; Tryggve Husebye; Višnja Ivancan; Kristjan Karason; Sundeep Kaul; Matti Kivikko; Janek Kubica; Josep Masip; Simon Matskeplishvili; Alexandre Mebazaa; Markku S Nieminen; Fabrizio Oliva; Julius G Papp; John Parissis; Alexander Parkhomenko; Pentti Põder; Gerhard Pölzl; Alexander Reinecke; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Toni Sarapohja; Robert H G Schwinger; Wolfgang Toller; Luigi Tritapepe; Carsten Tschöpe; Gerhard Wikström; Dirk von Lewinski; Bojan Vrtovec; Piero Pollesello
Journal:  J Cardiovasc Pharmacol       Date:  2020-07       Impact factor: 3.105

Review 9.  Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use.

Authors:  Zoltán Papp; Piergiuseppe Agostoni; Julian Alvarez; Dominique Bettex; Stefan Bouchez; Dulce Brito; Vladimir Černý; Josep Comin-Colet; Marisa G Crespo-Leiro; Juan F Delgado; Istvan Édes; Alexander A Eremenko; Dimitrios Farmakis; Francesco Fedele; Cândida Fonseca; Sonja Fruhwald; Massimo Girardis; Fabio Guarracino; Veli-Pekka Harjola; Matthias Heringlake; Antoine Herpain; Leo Ma Heunks; Tryggve Husebye; Višnja Ivancan; Kristjan Karason; Sundeep Kaul; Matti Kivikko; Janek Kubica; Josep Masip; Simon Matskeplishvili; Alexandre Mebazaa; Markku S Nieminen; Fabrizio Oliva; Julius-Gyula Papp; John Parissis; Alexander Parkhomenko; Pentti Põder; Gerhard Pölzl; Alexander Reinecke; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Toni Sarapohja; Robert Hg Schwinger; Wolfgang Toller; Luigi Tritapepe; Carsten Tschöpe; Gerhard Wikström; Dirk von Lewinski; Bojan Vrtovec; Piero Pollesello
Journal:  Card Fail Rev       Date:  2020-07-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.